Navigation Links
Study shows new treatment strategy effective for certain lung cancers
Date:3/10/2011

New Orleans, LA LSU oncologist Vince D. Cataldo, MD, is the lead author of a review article reporting two chemotherapy drugs now indicated for second and third-line therapy in patients with advanced non-small-cell lung cancer are remarkably effective in treating a certain subset of these patients. Dr. Cataldo, a Clinical Assistant Professor of Medicine at LSU Health Sciences Center New Orleans School of Medicine, practicing at LSU's Earl K. Long Medical Center and Hematology-Oncology Clinic in Baton Rouge, and his colleagues say these drugs should be considered as a first-line treatment in people who are known to carry an Epidermal Growth Factor Receptor (EGFR) mutation. The paper is published in the March 10, 2011 issue of the New England Journal of Medicine.

The drugs, Erlotinib and Gefitinib, which are in a class of highly-specific small molecule tyrosine kinase inhibitors, work by blocking the activation of EGFR which is involved in cell survival and growth, as well as the development of a nourishing blood supply and metastasis.

"Targeting the genetic mutation contributing to the development of the cancer, this class of drugs produced a response rate that exceeded 70% in these patients," notes Dr. Cataldo.

The drugs, taken by mouth, also had fewer side effects. Unlike traditional cytotoxic agents, Erlotinib and Gefitinib do not typically cause myelosuppression, neuropathy, alopecia, or severe nausea.

Lung cancer, the leading cause of cancer-related death worldwide, accounted for an estimated 157,300 deaths in the United States in 2010. Approximately 85 to 90% of all cases of lung cancer are nonsmall-cell lung cancer (NSCLC) which is also associated with smoking. Advanced-stage NSCLC is currently considered an incurable disease for which standard chemotherapy provides marginal improvement in overall survival at the expense of substantial morbidity and mortality. Furthermore, less than 30% of patients with metastatic NSCLC have a response to platinum-based chemotherapy, the most commonly used initial treatment in this stage of the disease. Even with the addition of newer agents, such as bevacizumab, to chemotherapy, the median overall survival of patients with metastatic NSCLC remains approximately 1 year, and only 3.5% of patients with metastatic NSCLC survive 5 years after diagnosis.

"The EGFR mutation is just one of the mutations associated with non-small-cell lung cancer," says Dr. Cataldo. "These results also provide a model for identifying others, which we are currently pursuing. Treatment targeting the causes of this cancer will not only improve quality of life, but may also improve survival of this devastating disease."

The University of Texas the University of Texas M.D. Anderson Cancer Center, and Montefiore Medical Center, Albert Einstein College of Medicine also participated in the review.


'/>"/>

Contact: Leslie Capo
lcapo@lsuhsc.edu
504-568-4806
Louisiana State University Health Sciences Center
Source:Eurekalert

Related biology news :

1. Study finds usage of, recommendations for supplements common within various physician specialties
2. Study provides explanation for connection between low birth weight and obesity later in life
3. New UF study shows some sharks follow mental map to navigate seas
4. Study shows how plants sort and eliminate genes over millennia
5. MBARI and Monterey Bay National Marine Sanctuary to study effects of shipping containers lost at sea
6. Rensselaer professor utilizing New York state grant to study adult stem cells
7. Study analyzes role of PARP enzyme in eukaryotes
8. Fossil bird study describes ripple effect of extinction in animal kingdom
9. University of Missouri researcher study provides insight into how corn makes hormones
10. Rainwater harvest study finds roofing material affects water quality
11. A study reveals the keys to the locomotion of snails
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2017)... , May 5, 2017 RAM ... announced a new breakthrough in biometric authentication based ... quantum mechanical properties to perform biometric authentication. These new ... semiconductor material created by Ram Group and its ... entertainment, transportation, supply chains and security. Ram Group ...
(Date:4/13/2017)... , April 13, 2017 UBM,s Advanced Design ... will feature emerging and evolving technology through its ... Summits will run alongside the expo portion of the ... panels and demonstrations focused on trending topics within 3D ... design and manufacturing event will take place June 13-15, 2017 ...
(Date:4/11/2017)... , April 11, 2017 NXT-ID, ... security technology company, announces the appointment of independent Directors Mr. ... to its Board of Directors, furthering the company,s corporate ... ... NXT-ID, we look forward to their guidance and benefiting from ...
Breaking Biology News(10 mins):
(Date:10/12/2017)... ... October 12, 2017 , ... They ... a complex biological network, a depiction of a system of linkages and connections ... Korkin, PhD, associate professor of computer science at Worcester Polytechnic Institute (WPI) and ...
(Date:10/12/2017)... , ... October 12, 2017 ... ... announces publication of a United States multicenter, prospective clinical study that demonstrates ... point-of-care diagnostic test capable of identifying clinically significant acute bacterial and viral ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the first-ever genomics analysis platform specifically designed for life science researchers to ... of pioneering researcher Rosalind Franklin, who made a major contribution to the ...
(Date:10/11/2017)... ... ... wash is a basic first aid supply for any work environment, but most personal eye ... first if a dangerous substance enters both eyes? It’s one less decision, and likely quicker ... eye piece. , “Whether its dirt and debris, or an acid or alkali, getting anything ...
Breaking Biology Technology: